{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:50:47Z","timestamp":1792673447496,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011606","name":"Open University of Sri Lanka","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiological Methods"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.mimet.2020.106127","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T10:49:18Z","timestamp":1608547758000},"page":"106127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Nano-based drug delivery optimization for tuberculosis treatment: A review"],"prefix":"10.1016","volume":"181","author":[{"given":"Madushani H.","family":"Dahanayake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil C.A.","family":"Jayasundera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mimet.2020.106127_bb0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1469-0691.2004.00758.x","article-title":"Tuberculosis in HIV-infected patients: a comprehensive review","volume":"10","author":"Aaron","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.mimet.2020.106127_bb0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijantimicag.2005.12.009","article-title":"Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses","volume":"27","author":"Ahmad","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.mimet.2020.106127_bb0015","first-page":"806","article-title":"Potential of nanoemulsions for intravenous delivery of rifampicin","volume":"63","author":"Ahmed","year":"2008","journal-title":"Pharmazie"},{"key":"10.1016\/j.mimet.2020.106127_bb0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1517\/17425247.3.1.139","article-title":"Polymeric micelles for drug delivery","volume":"3","author":"Aliabadi","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.mimet.2020.106127_bb0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/1817-1737.44778","article-title":"Diagnosis of latent tuberculosis: can we do better?","volume":"4","author":"Al-Orainey","year":"2009","journal-title":"Ann. Thorac. Med."},{"key":"10.1016\/j.mimet.2020.106127_bb0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/A:1010061013365","article-title":"Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages","volume":"2","author":"Anisimova","year":"2000","journal-title":"J. Nanoparticle Res."},{"key":"10.1016\/j.mimet.2020.106127_bb0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jmgm.2015.05.012","article-title":"Association of the anti-tuberculosis drug rifampicin with a PAMAM dendrimer","volume":"60","author":"Bellini","year":"2015","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.mimet.2020.106127_bb0040","first-page":"113","article-title":"Recent trends of drug used treatment of tuberculosis","volume":"1","author":"Bhowmik","year":"2009","journal-title":"J. Chem. Pharm. Res."},{"key":"10.1016\/j.mimet.2020.106127_bb0045","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1021\/cr970069y","article-title":"About dendrimers: structure, physical properties, and applications","volume":"99","author":"Bosman","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.mimet.2020.106127_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(94)00324-X","article-title":"Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery","volume":"116","author":"Brannon-Peppas","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejpb.2016.12.019","article-title":"Polymeric mixed micelles as nanomedicines: achievements and perspectives","volume":"113","author":"Cagel","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0060","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/QCO.0b013e328319bce6","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis\u00a0: a review","volume":"21","author":"Chan","year":"2008","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.mimet.2020.106127_bb0065","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1080\/03639045.2018.1506472","article-title":"Formulation, optimization and characterization of rifampicin loaded solid lipid nanoparticles for the treatment of tuberculosis","volume":"44","author":"Chokshi","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0070","first-page":"1","article-title":"Tuberculosis chemotherapy\u00a0: current drug delivery approaches","volume":"7","author":"Claire","year":"2006","journal-title":"Respir. Res."},{"key":"10.1016\/j.mimet.2020.106127_bb0075","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.addr.2007.10.013","article-title":"Advances in lipid nanodispersions for parenteral drug delivery and targeting","volume":"60","author":"Constantinides","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mimet.2020.106127_bb0080","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1183\/09031936.00007814","article-title":"Xpert MTB\/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis","volume":"44","author":"Denkinger","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.mimet.2020.106127_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0304-4165(96)00088-8","article-title":"Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice","volume":"1334","author":"Deol","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mimet.2020.106127_bb0090","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.41.6.1211","article-title":"Therapeutic efficacies of isoniazid and rifampin encapsulated in lung- specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice","volume":"41","author":"Deol","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mimet.2020.106127_bb0095","series-title":"A Systematic Review of Rapid Diagnostic Tests for the Detection of Tuberculosis Infection. How do I Get a Copy of HTA on CD? HTA Background, HTA Heal. Technol. Assess","volume":"11","author":"Dinnes","year":"2007"},{"key":"10.1016\/j.mimet.2020.106127_bb0100","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4103\/0250-474X.29622","article-title":"Niosomal system for delivery of rifampicin to lymphatics","volume":"68","author":"Dixit","year":"2006","journal-title":"Ind. J. Pharm. Sci."},{"key":"10.1016\/j.mimet.2020.106127_bb0105","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/jps.22428","article-title":"Polyamidoamine dendrimers can improve the pulmonary absorption of insulin and calcitonin in rats","volume":"100","author":"Dong","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.mimet.2020.106127_bb0110","series-title":"Drug Resistant Tuberculosis Fact Sheet","year":"2016"},{"key":"10.1016\/j.mimet.2020.106127_bb0115","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1128\/AAC.40.11.2618","article-title":"Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin","volume":"40","author":"D\u00fczg\u00fcne\u015f","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mimet.2020.106127_bb0120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.09.017","article-title":"Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis","volume":"330","author":"El-Ridy","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0125","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/03639045.2011.560605","article-title":"Niosomal encapsulation of the antitubercular drug, pyrazinamide","volume":"37","author":"El-ridy","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1590\/0074-02760150454","article-title":"Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates","volume":"111","author":"Ferraz-Carvalho","year":"2016","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.mimet.2020.106127_bb0135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1590\/S1516-93322004000100008","article-title":"Analysis of the molecular association of rifampicin with hydroxypropyl-\u03b2-cyclodextrin","volume":"40","author":"Ferreira","year":"2004","journal-title":"Rev. Bras. Ciencias Farm. J. Pharm. Sci."},{"key":"10.1016\/j.mimet.2020.106127_bb0140","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1166\/jbn.2015.2091","article-title":"Hyaluronic acid-tocopherol succinate-based self-assembling micelles for targeted delivery of rifampicin to alveolar macrophages","volume":"11","author":"Gao","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.mimet.2020.106127_bb0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijantimicag.2007.08.008","article-title":"Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis","volume":"31","author":"Gaspar","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.mimet.2020.106127_bb0150","series-title":"Encyclopedia of Infectious Diseases: Modern Methodologies","first-page":"2008","volume":"14","author":"Goodman","year":"2008"},{"key":"10.1016\/j.mimet.2020.106127_bb0155","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT)","volume":"198","author":"Grif","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.mimet.2020.106127_bb0160","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrmicro2437","article-title":"Nanobead-based interventions for the treatment and prevention of tuberculosis","volume":"8","author":"Griffiths","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.mimet.2020.106127_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jddst.2017.06.009","article-title":"Nanoscale Kolliphor\u00ae HS 15 micelles to minimize rifampicin self-aggregation in aqueous media","volume":"41","author":"Grotz","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.mimet.2020.106127_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-018-2497-z","article-title":"Nanotechnology in tuberculosis: state of the art and the challenges ahead","volume":"35","author":"Grotz","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.mimet.2020.106127_bb0175","doi-asserted-by":"crossref","first-page":"101170","DOI":"10.1016\/j.jddst.2019.101170","article-title":"Pulmonary delivery of rifampicin-loaded soluplus micelles against Mycobacterium tuberculosis","volume":"53","author":"Grotz","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.mimet.2020.106127_bb0180","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4103\/0253-7613.71887","article-title":"Novel technologies: a weapon against tuberculosis","volume":"42","author":"Hari","year":"2010","journal-title":"Ind. J. Pharmacol."},{"key":"10.1016\/j.mimet.2020.106127_bb0185","doi-asserted-by":"crossref","first-page":"124755","DOI":"10.1016\/j.colsurfa.2020.124755","article-title":"Cationic rifampicin nanoemulsion for the treatment of ocular tuberculosis","volume":"597","author":"Henostroza","year":"2020","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.mimet.2020.106127_bb0190","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2147\/IJN.S236277","article-title":"Novel approach for transdermal delivery of rifampicin to induce synergistic antimycobacterial effects against cutaneous and systemic tuberculosis using a cationic nanoemulsion gel","volume":"15","author":"Hussain","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.mimet.2020.106127_bb0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/02652049509087252","article-title":"Preparation and characterization of niosomes containing rifampicin for lung targeting","volume":"12","author":"Jain","year":"1995","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.mimet.2020.106127_bb0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.colsurfb.2008.01.023","article-title":"Monolayers of the lipid derivatives of isoniazid at the air\/water interface and the formation of self-assembled nanostructures in water","volume":"64","author":"Jin","year":"2008","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.mimet.2020.106127_bb0205","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/713840401","article-title":"Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation","volume":"10","author":"Justo","year":"2003","journal-title":"Drug Deliv."},{"key":"10.1016\/j.mimet.2020.106127_bb0210","author":"Kanabus"},{"key":"10.1016\/j.mimet.2020.106127_bb0215","first-page":"224","article-title":"Preparation, characterization and tissue disposition of niosomes containing isoniazid","volume":"1","author":"Karki","year":"2008","journal-title":"Rasayan J. Chem."},{"key":"10.1016\/j.mimet.2020.106127_bb0220","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijpharm.2007.05.062","article-title":"Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis","volume":"345","author":"Kisich","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0225","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/AAC.34.6.967","article-title":"Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice","volume":"34","author":"Klemens","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mimet.2020.106127_bb0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.colsurfa.2019.01.004","article-title":"Formulation and optimization of long acting dual niosomes using Box- Behnken experimental design method for combinative delivery of Ethionamide and D-cycloserine in Tuberculosis treatment","volume":"565","author":"Kulkarni","year":"2019","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.mimet.2020.106127_bb0235","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/10611860600825159","article-title":"Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers","volume":"14","author":"Kumar","year":"2006","journal-title":"J. Drug Target."},{"key":"10.1016\/j.mimet.2020.106127_bb0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/156720107779314794","article-title":"PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug","volume":"4","author":"Kumar","year":"2007","journal-title":"Curr. Drug Deliv."},{"issue":"3","key":"10.1016\/j.mimet.2020.106127_bb0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5138\/ijdd.2010.0975.0215.03051","article-title":"Nanotechnology: a focus on treatment of tuberculosis","volume":"3","author":"Kumar","year":"2011","journal-title":"Int. J. Drug Deliv."},{"key":"10.1016\/j.mimet.2020.106127_bb0250","first-page":"14","article-title":"Dry powder inhaler - formulation aspects","volume":"44","author":"Kumaresan","year":"2012","journal-title":"Pharma Times"},{"key":"10.1016\/j.mimet.2020.106127_bb0255","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0924-8579(02)00175-9","article-title":"Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes","volume":"20","author":"Labana","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.mimet.2020.106127_bb0260","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11904-010-0054-4","article-title":"New antituberculous drugs in development","volume":"7","author":"Lalloo","year":"2010","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.mimet.2020.106127_bb0265","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.42.2.459","article-title":"Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection","volume":"42","author":"Leitzke","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mimet.2020.106127_bb0270","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1128\/AAC.49.6.2294-2301.2005","article-title":"Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models","volume":"49","author":"Lenaerts","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mimet.2020.106127_bb0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0280","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/08982100802564628","article-title":"In vitro uptake and antimycobacterial activity of liposomal usnic acid formulation","volume":"19","author":"Lira","year":"2009","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.mimet.2020.106127_bb0285","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cis.2012.08.002","article-title":"Niosomes\u00a0: novel sustained release nonionic stable vesicular systems \u2014 an overview","volume":"183\u2013184","author":"Mahale","year":"2012","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.mimet.2020.106127_bb0290","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1128\/AAC.00700-16","article-title":"Pulmonary deposition and elimination of liposomal amikacin for inhalation and effect on macrophage function after administration in rats","volume":"60","author":"Malinin","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mimet.2020.106127_bb0295","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijpharm.2017.04.044","article-title":"Chitosan and hyaluronan coated liposomes for pulmonary administration of curcumin","volume":"525","author":"Manconi","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0300","first-page":"1","article-title":"Impact of nanotechnology on hair attributes","volume":"3","author":"McAllister","year":"2007","journal-title":"ACS Nano"},{"key":"10.1016\/j.mimet.2020.106127_bb0305","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.colsurfb.2012.07.006","article-title":"Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs","volume":"101","author":"Mehta","year":"2013","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.mimet.2020.106127_bb0310","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.colsurfb.2011.05.018","article-title":"Quantitative investigation, stability and in vitro release studies of anti-TB drugs in triton niosomes","volume":"87","author":"Mehta","year":"2011","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.mimet.2020.106127_bb0315","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.colsurfb.2010.05.016","article-title":"Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles","volume":"79","author":"Moretton","year":"2010","journal-title":"Colloids Surfaces B Biointerfaces."},{"key":"10.1016\/j.mimet.2020.106127_bb0320","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1098\/rsif.2011.0414","article-title":"Cryoprotection-lyophilization and physical stabilization of rifampicin-loaded flower-like polymeric micelles","volume":"9","author":"Moretton","year":"2012","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.mimet.2020.106127_bb0325","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2217\/nnm.13.154","article-title":"Rifampicin-loaded \u201cflower-like\u201d polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid","volume":"9","author":"Moretton","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.mimet.2020.106127_bb0330","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.colsurfb.2015.10.049","article-title":"Nanopolymersomes as potential carriers for rifampicin pulmonary delivery","volume":"136","author":"Moretton","year":"2015","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.mimet.2020.106127_bb0335","series-title":"Nanotechnology-based Approaches Tuberc. Treat","first-page":"143","article-title":"Chapter 9 - Nanotechnology-based approaches for tuberculosis treatment","year":"2020"},{"key":"10.1016\/j.mimet.2020.106127_bb0340","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1773-2247(04)50020-5","article-title":"Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat","volume":"14","author":"Mullaicharam","year":"2004","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.mimet.2020.106127_bb0345","first-page":"1","article-title":"Nanotechnology-based approach in tuberculosis treatment","volume":"2017","author":"Nasiruddin","year":"2017","journal-title":"Tuberc. Res. Treat."},{"key":"10.1016\/j.mimet.2020.106127_bb0350","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijpharm.2013.11.023","article-title":"PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization","volume":"461","author":"Nasr","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0355","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1128\/AAC.39.9.2104","article-title":"Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection","volume":"39","author":"Oh","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mimet.2020.106127_bb0360","series-title":"B49. Non-tuberculous Mycobact. Dis. Case Reports","first-page":"A3732","article-title":"Airway deposition and retention of liposomal amikacin for inhalation in patients with pulmonary nontuberculous mycobacterial disease","author":"Olivier","year":"2016"},{"key":"10.1016\/j.mimet.2020.106127_bb0365","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.mimet.2020.106127_bb0370","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nantod.2012.01.002","article-title":"Polymeric micelle stability","volume":"7","author":"Owen","year":"2012","journal-title":"Nano Today"},{"key":"10.1016\/j.mimet.2020.106127_bb0375","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0380","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000110009","article-title":"Nanoparticle-based oral drug delivery system for an injectable antibiotic \u2013 evaluation in a murine tuberculosis model","volume":"53","author":"Pandey","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.mimet.2020.106127_bb0385","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tube.2004.11.003","article-title":"Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis"},{"key":"10.1016\/j.mimet.2020.106127_bb0390","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.tube.2003.07.001","article-title":"Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis","volume":"83","author":"Pandey","year":"2003","journal-title":"Tuberculosis"},{"key":"10.1016\/j.mimet.2020.106127_bb0395","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijantimicag.2004.01.002","article-title":"Liposome-based antitubercular drug therapy in a Guinea pig model of tuberculosis","volume":"23","author":"Pandey","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.mimet.2020.106127_bb0400","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.tube.2005.08.009","article-title":"Oral solid lipid nanoparticle-based antitubercular chemotherapy","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis"},{"key":"10.1016\/j.mimet.2020.106127_bb0405","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/CMR.00059-10","article-title":"Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities","volume":"24","author":"Parsons","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.mimet.2020.106127_bb0410","first-page":"139","article-title":"Significance of particulate drug delivery system in anti-microbial therapy","volume":"5","author":"Patil","year":"2016","journal-title":"Adv. Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.mimet.2020.106127_bb0415","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijpharm.2014.12.009","article-title":"Pulmonary drug delivery systems for tuberculosis treatment","volume":"478","author":"Pham","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0420","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0378-5173(86)90201-2","article-title":"Hydroxypropyl-\u03b2-cyclodextrin: preparation and characterization; effects on solubility of drugs","volume":"29","author":"Pitha","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0425","doi-asserted-by":"crossref","first-page":"190035","DOI":"10.1183\/16000617.0035-2019","article-title":"Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives","volume":"28","author":"Pontali","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.mimet.2020.106127_bb0430","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijpharm.2017.03.089","article-title":"Development of extended-voyaging anti-oxidant linked amphiphilic polymeric nanomicelles for anti-tuberculosis drug delivery","volume":"524","author":"Praphakar","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0435","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","article-title":"Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems","volume":"182","author":"Prevots","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.mimet.2020.106127_bb0440","first-page":"379","article-title":"Formulation and evaluation of rifampicin and gatifloxacin niosomes on logarithmic-phase cultures of Mycobacterium tuberculosis","volume":"1","author":"Rani","year":"2010","journal-title":"Int. J. Pharma Bio Sci."},{"key":"10.1016\/j.mimet.2020.106127_bb0445","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1208\/s12249-018-1151-8","article-title":"Smartly engineered PEGylated Di-block nanopolymeric micelles: duo delivery of isoniazid and rifampicin against Mycobacterium tuberculosis","volume":"19","author":"Rani","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.mimet.2020.106127_bb0450","first-page":"5","article-title":"Nanosuspension as the most promising approach in nanoparticulate drug delivery systems","volume":"59","author":"Rao","year":"2004","journal-title":"Pharmazie"},{"key":"10.1016\/j.mimet.2020.106127_bb0455","first-page":"37","article-title":"Physicochemical characterization of \u03b2-cyclodextrin and hydroxy ethyl \u03b2-cyclodextrin complexes of rifampicin","volume":"47","author":"Rao","year":"2006","journal-title":"Ars Pharm."},{"key":"10.1016\/j.mimet.2020.106127_bb0460","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/10717544.2012.721144","article-title":"Inhaled pyrazinamide proliposome for targeting alveolar macrophages","volume":"19","author":"Rojanarat","year":"2012","journal-title":"Drug Deliv."},{"key":"10.1016\/j.mimet.2020.106127_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108703","article-title":"Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection","volume":"9","author":"Rose","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.mimet.2020.106127_bb0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a017863","article-title":"Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis","volume":"5","author":"Seung","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.mimet.2020.106127_bb0475","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1080\/10717544.2017.1384298","article-title":"Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment","volume":"24","author":"Shah","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.mimet.2020.106127_bb0480","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12098-020-03230-1","article-title":"Multi-drug resistant and extensively-drug resistant tuberculosis","volume":"87","author":"Shah","year":"2020","journal-title":"Indian J. Pediatr."},{"key":"10.1016\/j.mimet.2020.106127_bb0485","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11094-008-0073-2","article-title":"Development of a nanosomal formulation of moxifloxacin based on poly(butyl-2-cyanoacrylate)","volume":"42","author":"Shipulo","year":"2008","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.mimet.2020.106127_bb0490","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-019-01095-z","article-title":"Amikacin liposome inhalation suspension: a review in Mycobacterium avium complex lung disease","volume":"79","author":"Shirley","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.mimet.2020.106127_bb0495","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ardp.200500039","article-title":"Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug","volume":"339","author":"Silva","year":"2006","journal-title":"Arch. Pharm. (Weinheim.)"},{"key":"10.1016\/j.mimet.2020.106127_bb0500","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4314\/tjpr.v6i4.14665","article-title":"Preparation of polymeric micelles for use as carriers of tuberculostatic drugs","volume":"6","author":"Silva","year":"2007","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.mimet.2020.106127_bb0505","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4314\/tjpr.v10i2.66564","article-title":"Niosomal delivery of isoniazid: development and characterization","volume":"10","author":"Singh","year":"2011","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.mimet.2020.106127_bb0510","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.addr.2009.11.023","article-title":"New old challenges in tuberculosis\u00a0: potentially effective nanotechnologies in drug delivery","volume":"62","author":"Sosnik","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mimet.2020.106127_bb0515","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jiac.2017.10.009","article-title":"Sensitivity and specificity of QuantiFERON-TB gold plus compared with QuantiFERON-TB gold in-tube and T-SPOT.TB on active tuberculosis in Japan","volume":"24","author":"Takasaki","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.mimet.2020.106127_bb0520","series-title":"Adv. Biomater. Biodevices","first-page":"487","article-title":"Nanoparticles: scope in drug delivery","author":"Tanwar","year":"2014"},{"key":"10.1016\/j.mimet.2020.106127_bb0525","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2008.04.007","article-title":"Formulation of rifampicin \u2013 cyclodextrin complexes for lung nebulization","volume":"129","author":"Tewes","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.mimet.2020.106127_bb0530","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.nano.2016.08.031","article-title":"System with embedded drug release and nanoparticle degradation sensor showing efficient rifampicin delivery into macrophages","volume":"13","author":"Trousil","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.mimet.2020.106127_bb0535","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1007\/s11095-017-2206-3","article-title":"Conjugated and entrapped HPMA-PLA Nano-polymeric micelles based dual delivery of first line anti TB drugs: improved and safe drug delivery against sensitive and resistant Mycobacterium tuberculosis","volume":"34","author":"Upadhyay","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.mimet.2020.106127_bb0540","series-title":"Arikayce\u00ae (Amikacin Liposome Inhalation Suspension): US Prescribing Information","volume":"2018","author":"US FDA","year":"2018"},{"key":"10.1016\/j.mimet.2020.106127_bb0545","first-page":"4109","article-title":"Nanoparticulate technology in the treatment of tuberculosis: a review","volume":"9","author":"Varghese","year":"2018","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"10.1016\/j.mimet.2020.106127_bb0550","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/nnm-2017-0143","article-title":"Functional nanocarrier for drug and gene delivery via local administration in mucosal tissues","volume":"13","author":"Wang","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.mimet.2020.106127_bb0555","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","article-title":"Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges","volume":"17","author":"Wen","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.mimet.2020.106127_bb0560","series-title":"Global Tuberculosis Report 2018","first-page":"2018","author":"WHO","year":"2018"},{"key":"10.1016\/j.mimet.2020.106127_bb0565","series-title":"Global Tuberculosis Report 2019","first-page":"2019","author":"WHO","year":"2019"},{"key":"10.1016\/j.mimet.2020.106127_bb0570","series-title":"WHO Operational Handbook on Tuberculosis","author":"WHO","year":"2020"},{"key":"10.1016\/j.mimet.2020.106127_bb0575","series-title":"Tuberculosis Fact Sheet 2020","author":"WHO","year":"2020"},{"key":"10.1016\/j.mimet.2020.106127_bb0580","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.addr.2003.12.002","article-title":"Solid lipid nanoparticles for parenteral drug delivery","volume":"56","author":"Wissing","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mimet.2020.106127_bb0585","series-title":"Chest Radiography in Tuberculosis Detection: Summary of Current WHO Recommendations and Guidance on Programmatic Approaches","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.mimet.2020.106127_bb0590","series-title":"Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.mimet.2020.106127_bb0595","author":"World Health Organization"},{"key":"10.1016\/j.mimet.2020.106127_bb0600","author":"World Health Organization"},{"key":"10.1016\/j.mimet.2020.106127_bb0605","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Microbiol."}],"container-title":["Journal of Microbiological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167701220308435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167701220308435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:01:49Z","timestamp":1759104109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167701220308435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":121,"alternative-id":["S0167701220308435"],"URL":"https:\/\/doi.org\/10.1016\/j.mimet.2020.106127","relation":{},"ISSN":["0167-7012"],"issn-type":[{"value":"0167-7012","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nano-based drug delivery optimization for tuberculosis treatment: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mimet.2020.106127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106127"}}